Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalproex sodium extended-release add-on therapy for adult complex partial seizures
ChiCTR2400087350Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of divalproex sodium in complex partial epilepsy (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Proportion of patients with at least 50% reduction in complex partial seizure frequency. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
divalproex sodium
03
Conditions
complex partial epilepsy
Beyond the preview
Go deeper on ChiCTR2400087350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087350.